Business Wire

BUREAU VERITAS CERTIFICATION Publishes the World’s First Personal Data Protection Standard

Del

Bureau Veritas Certification has released a technical standard and certification to support companies in their digital transformation and promote confidence in big data.

The new certification from Bureau Veritas Certification is based on the world's first technical standard focused on the management of personal data protection by companies. This standard was prepared by Bureau Veritas Certification, in collaboration with Lexing®, an international network of lawyers specialized in personal data protection.

The purpose is to offer companies an established, independent and credible certification pertaining to the management of the personal data they collect. Certified companies will be able to demonstrate that they manage the personal data they collect in accordance with regulatory requirements and the expectations of their stakeholders.

The new certification anticipates the General Data Protection Regulation (GDPR), which is due to come into force in May 2018 across all 28 European Union member states. The Regulation applies to companies based anywhere in the world that process or hold the personal data of EU citizens.

Furthermore, 80-90% of citizens have expressed concern regarding the protection of their personal data. Data breaches, global cyberattacks and leaks of classified information have now become regular occurrences. This climate of distrust has tended to intensify with big data, even as the General Data Protection Regulation will require organizations that process data to comply with much higher standards.

"Digital responsibility has emerged as one of the major challenges facing companies in coming years. Our framework integrates standards for managing the protection of personal data, such as obtaining consent, proportionality and retention periods, without fundamentally changing a company’s processes or structure", said Sébastien Fox, Vice President Certification Service Line, Bureau Veritas Group.

Companies need to take the lead and anticipate digital transformation by going beyond mere compliance with regulations. Responsible data management will give certified companies an additional way to protect and differentiate their brands, while restoring the trust of consumers, customers, patients and other stakeholders.

"All these steps will only be reassuring if they are clear, and if the assurances given about the protection of individuals’ fundamental rights and freedoms are credible. On this point, only an independent third party can legitimately affirm that ethical rules have been respected. As a global leader in certification, Bureau Veritas Certification is now working with companies in all sectors who want to engage in a rigorous and transparent manner," said Philippe Jeanmart, Senior Vice President Technical, Quality & Risk, Bureau Veritas.

According to Alain Bensoussan, Lexing’s Founder and President, "at a time when this Regulation marks a major turning point in the regulation of personal data, we are pleased and proud to have developed a technical standard to integrateGDPR requirements into company processes in partnership with Bureau Veritas, a world leader in its sector". And the lawyer added: "This framework will allow companies to attest their compliance with the new requirements arising from the Regulation and to enable them, in the face of this upheaval of their digital environment and the changing rules of the data game, to ensure that they have anticipated and implemented the essential measures necessary to be ready by May 2018".

About Bureau Veritas

Bureau Veritas is a world-leading provider in laboratory testing, inspection and certification. Created in 1828, the Group has more than 69,000 employees in around 1,400 offices and laboratories all across the world. Bureau Veritas helps its clients to improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.

Bureau Veritas is listed on Euronext Paris and belongs to the Next 20 index.

Compartment A, code ISIN FR 0006174348, stock symbol: BVI.

For more information, visit www.bureauveritas.com

About Lexing

Lexing is the first international network of lawyers dedicated to digital and technology law. Lexing® allows multinationals to benefit from the assistance of seasoned lawyers worldwide with established competence in the field of new technologies in their respective countries. Techniques and businesses are the same in all countries; the only differentiating factor is the law applicable to them. The Lexing® network now comprises some thirty law firms on all 5 continents.

For more information, visit https://www.alain-bensoussan.com/, https://lexing.network/fr

Contact information

Bureau Veritas Media Contact:
Hélène RIBA
helene.riba@bureauveritas.com
or
Lexing Media Contact:
Eric BONNET
eric-bonnet@alain-bensoussan.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

AURAK Gains SACSCOC Accreditation15.12.2018 10:49Pressemelding

The Southern Association of Colleges and Schools Commission on Colleges (SACSCOC) officially announced the accreditation of the American University of Ras Al Khaimah (AURAK) at its 2018 Annual Meeting which was held in New Orleans, Louisiana, in the United States of America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181215005017/en/ AURAK delegation during the SACSCOC conference in New Orleans” (Photo: AETOSWire) SACSCOC, the regional body for the accreditation of degree-granting higher education institutions in the Southern United States, has a membership of more than 800 institutions in the Southern states and other international sites approved by SACSCOC that award associate, baccalaureate, master’s, and/or doctoral degrees. SACSCOC also awards accreditation to other international institutions of higher education that satisfy all its requirements and demonstrate compliance with its accreditation standards. AURAK now

Lehman Brothers Treasury Announces Plans for Partial Wind-Down14.12.2018 17:41Pressemelding

Lehman Brothers Treasury Co. B.V. in liquidation (“LBT”) today, through its U.S. counsel Kramer Levin Naftalis & Frankel LLP, announced that LBT is planning a final cash distribution to its creditors. Professional holders of eligible notes will have the option to retain their investment by electing to receive substitute notes of one (or a few) series. Such election shall take place through a solicitation process. As a consequence, LBT will be able to reduce the number of series of notes outstanding from more than 3,700 to one or a few. Noteholders electing to receive substitute notes will be afforded the same economic entitlement to distributions received by LBT from Lehman Brothers Holdings Inc. (“LBHI”) through the substitute notes. The substitute notes will be denominated in U.S. dollars and future distributions will be made in U.S. dollars only. Noteholders who are not professional investors, or hold notes that are not eligible for substitution, or do not elect to receive substitut

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage IV Hodgkin Lymphoma in Combination with AVD14.12.2018 17:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the extension of the marketing authorization of ADCETRIS (brentuximab vedotin) and recommended its approval in combination with AVD in adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma. ADCETRIS is currently not approved as a therapy for previously untreated Hodgkin lymphoma in Europe. “For a large number of previously untreated Hodgkin lymphoma patients diagnosed with Stage IV disease, progression will occur with current treatments, highlighting a true unmet need in this population,” said Anna Sureda, M.D., Ph.D., Head of the Hematology Department and Hematopoietic Stem Cell Transplant Programme, Institut Català d'Oncologia - Hospital Duran i Reynals. “In the ECHELON-1 cl

Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42Pressemelding

Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00

Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00Pressemelding

Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07Pressemelding

Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha